141 related articles for article (PubMed ID: 216831)
1. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report.
Malik MO; Banatvala J; Hutt MS; Abu-Sin AY; Hidaytallah A; El-Hadi AE
J Natl Cancer Inst; 1979 Feb; 62(2):221-4. PubMed ID: 216831
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
3. EBV-specific humoral antibodies in nasopharyngeal carcinoma patients in Cuba.
Ruiz R; Gurtsevich V; Le Riverend E
Neoplasma; 1979; 26(2):125-31. PubMed ID: 224330
[TBL] [Abstract][Full Text] [Related]
4. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma].
Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P
Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136
[TBL] [Abstract][Full Text] [Related]
5. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
6. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
7. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
Kuljić-Kapulica N
Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
[TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
9. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
Shimakage M; Ikegami N; Chatani M; Yoshino K; Sato T
Biken J; 1987 Jun; 30(2):45-51. PubMed ID: 2830879
[TBL] [Abstract][Full Text] [Related]
10. Malaria antibody levels in patients with nasopharyngeal carcinoma.
Yadav M; Prasad U
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand.
Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P
Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
Kottaridis SD; Goula I; Kiparissiadis P
Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
[No Abstract] [Full Text] [Related]
13. Immune response to Epstein-Barr virus (EBV) in ataxia-telangiectasia: EBV-specific antibody patterns and their relation to cell-mediated immunity.
Berkel AI; Henle W; Henle G; Ersoy F; Sanal O; Klein G; Yeğin O
Kroc Found Ser; 1985; 19():287-300. PubMed ID: 2999343
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal carcinoma and Epstein-Barr virus. III. The detection of anti-nuclear antibodies.
Lynn TC; Hsu MM; Hsieh T; Tu SM; Hamajima K
Jpn J Exp Med; 1976 Oct; 46(5):289-95. PubMed ID: 189106
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma.
Tan RS; Li JS; Grill SP; Nutter LM; Cheng YC
Cancer Res; 1986 Oct; 46(10):5024-8. PubMed ID: 3019519
[TBL] [Abstract][Full Text] [Related]
16. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
[TBL] [Abstract][Full Text] [Related]
17. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong.
Lo S; Ho WK; Wei WI
Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561
[TBL] [Abstract][Full Text] [Related]
19. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
[No Abstract] [Full Text] [Related]
20. Epstein-Barr virus-related lymphocyte stimulation inhibitor: a possible prognostic tool for undifferentiated nasopharyngeal carcinoma.
Kamaraju LS; Levine PH; Sundar SK; Ablashi DV; Faggioni A; Armstrong GR; Bertram G; Krueger GR
J Natl Cancer Inst; 1983 Apr; 70(4):643-7. PubMed ID: 6300502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
